Pharma major Lupin Limited (Lupin) announced the launch of Divalproex Sodium Extended-Release (ER) Tablets USP, 250 mg and 500 mg, having received approval from the United States Food and Drug Administration (U.S. FDA) earlier. The product will be manufactured at Lupin’s Nagpur facility in India.

Divalproex Sodium ER Tablets USP, 250 mg and 500 mg, is the generic equivalent of Depakote Extended-Release (ER) Tablets, 250 mg, and 500 mg, of AbbVie Inc., indicated for:

Divalproex Sodium Extended-Release (ER) Tablets USP (RLD: Depakote ER) had annual sales of approximately USD 130 million in the U.S. (IQVIA MAT July 2020).

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and the Middle-East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the 3rd largest pharmaceutical company in the U.S. by prescriptions and 5th in India by global revenues. The Company invests 9.6 % of its revenues on research and development.

Lupin has fifteen manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.